454 related articles for article (PubMed ID: 19074476)
1. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
2. Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
Zheng J; Tian J; Wang S; Hu P; Wu Q; Shan X; Zhao P; Zhang C; Guo W; Xu M; Chen H; Lu R
Eur J Pharmacol; 2020 Sep; 883():173386. PubMed ID: 32712088
[TBL] [Abstract][Full Text] [Related]
3. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
[TBL] [Abstract][Full Text] [Related]
4. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
[TBL] [Abstract][Full Text] [Related]
5. 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload.
Patten RD; Pourati I; Aronovitz MJ; Alsheikh-Ali A; Eder S; Force T; Mendelsohn ME; Karas RH
J Card Fail; 2008 Apr; 14(3):245-53. PubMed ID: 18381189
[TBL] [Abstract][Full Text] [Related]
6. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
[TBL] [Abstract][Full Text] [Related]
7. Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
Yin Z; Wang X; Zhang L; Zhou H; Wei L; Dong X
Cardiovasc Ther; 2016 Feb; 34(1):21-9. PubMed ID: 26506219
[TBL] [Abstract][Full Text] [Related]
8. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
Finsen AV; Lunde IG; Sjaastad I; Østli EK; Lyngra M; Jarstadmarken HO; Hasic A; Nygård S; Wilcox-Adelman SA; Goetinck PF; Lyberg T; Skrbic B; Florholmen G; Tønnessen T; Louch WE; Djurovic S; Carlson CR; Christensen G
PLoS One; 2011; 6(12):e28302. PubMed ID: 22164265
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin activity is required for cardiac remodelling in pregnancy.
Chung E; Yeung F; Leinwand LA
Cardiovasc Res; 2013 Dec; 100(3):402-10. PubMed ID: 23985902
[TBL] [Abstract][Full Text] [Related]
11. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
[TBL] [Abstract][Full Text] [Related]
12. Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload.
Gelpi RJ; Gao S; Zhai P; Yan L; Hong C; Danridge LM; Ge H; Maejima Y; Donato M; Yokota M; Molkentin JD; Vatner DE; Vatner SF; Sadoshima J
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1814-9. PubMed ID: 19717730
[TBL] [Abstract][Full Text] [Related]
13. Increased cholinergic activity under conditions of low estrogen leads to adverse cardiac remodeling.
Teixeira VP; Miranda K; Scalzo S; Rocha-Resende C; Silva MM; Tezini GCSV; Melo MB; Souza-Neto FP; Silva KSC; Jesus ICG; Santos AK; de Oliveira M; Szawka RE; Salgado HC; Prado MAM; Poletini MO; Guatimosim S
Am J Physiol Cell Physiol; 2021 Apr; 320(4):C602-C612. PubMed ID: 33296286
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta protects the murine heart against left ventricular hypertrophy.
Babiker FA; Lips D; Meyer R; Delvaux E; Zandberg P; Janssen B; van Eys G; Grohé C; Doevendans PA
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1524-30. PubMed ID: 16627800
[TBL] [Abstract][Full Text] [Related]
15. Inorganic arsenic induces sex-dependent pathological hypertrophy in the heart.
Kabir R; Sinha P; Mishra S; Ebenebe OV; Taube N; Oeing CU; Keceli G; Chen R; Paolocci N; Rule A; Kohr MJ
Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1321-H1336. PubMed ID: 33481702
[TBL] [Abstract][Full Text] [Related]
16. Triad3A attenuates pathological cardiac hypertrophy involving the augmentation of ubiquitination-mediated degradation of TLR4 and TLR9.
Lu X; He Y; Tang C; Wang X; Que L; Zhu G; Liu L; Ha T; Chen Q; Li C; Xu Y; Li J; Li Y
Basic Res Cardiol; 2020 Feb; 115(2):19. PubMed ID: 32008145
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
18. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Xu X; Zhang P; Kwak D; Fassett J; Yue W; Atzler D; Hu X; Liu X; Wang H; Lu Z; Guo H; Schwedhelm E; Böger RH; Chen P; Chen Y
Basic Res Cardiol; 2017 Aug; 112(5):55. PubMed ID: 28819685
[TBL] [Abstract][Full Text] [Related]
19. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
20. 17beta-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats.
Wu CH; Liu JY; Wu JP; Hsieh YH; Liu CJ; Hwang JM; Lee SD; Chen LM; Chang MH; Kuo WW; Shyu JC; Tsai JH; Huang CY
Life Sci; 2005 Dec; 78(4):347-56. PubMed ID: 16183079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
